Controlled Substances Act
PART
B - AUTHORITY TO CONTROL; STANDARDS AND SCHEDULES
§ 811. Authority and criteria for classification of substances.
- (a) Rules and regulations of Attorney General; hearing
The Attorney General shall apply the provisions of this subchapter to the controlled
substances listed in the schedules established by section 812 of this title
and to any other drug or other substance added to such schedules under this
subchapter. Except as provided in subsections (d) and (e) of this section, the
Attorney General may by rule -
- (1) add to such a schedule or transfer between such schedules any drug or
other substance if he -
- (A) finds that such drug or other substance has a potential for abuse,
and
- (B) makes with respect to such drug or other substance the findings
prescribed by subsection (b) of section 812 of this title for the schedule
in which such drug is to be placed; or
- (2) remove any drug or other substance from the schedules if he finds that
the drug or other substance does not meet the requirements for inclusion in
any schedule.
Rules of the Attorney General under this subsection shall be made on the record
after opportunity for a hearing pursuant to the rulemaking procedures prescribed
by subchapter II of chapter 5 of title 5. Proceedings for the issuance, amendment,
or repeal of such rules may be initiated by the Attorney General (1) on his
own motion, (2) at the request of the Secretary, or (3) on the petition of any
interested party.
- (b) Evaluation of drugs and other substances
The Attorney General shall, before initiating proceedings under subsection
(a) of this section to control a drug or other substance or to remove a drug
or other substance entirely from the schedules, and after gathering the necessary
data, request from the Secretary a scientific and medical evaluation, and his
recommendations, as to whether such drug or other substance should be so controlled
or removed as a controlled substance. In making such evaluation and recommendations,
the Secretary shall consider the factors listed in paragraphs (2), (3), (6),
(7), and (8) of subsection (c) of this section and any scientific or medical
considerations involved in paragraphs (1), (4), and (5) of such subsection.
The recommendations of the Secretary shall include recommendations with respect
to the appropriate schedule, if any, under which such drug or other substance
should be listed. The evaluation and the recommendations of the Secretary shall
be made in writing and submitted to the Attorney General within a reasonable
time. The recommendations of the Secretary to the Attorney General shall be
binding on the Attorney General as to such scientific and medical matters, and
if the Secretary recommends that a drug or other substance not be controlled,
the Attorney General shall not control the drug or other substance. If the Attorney
General determines that these facts and all other relevant data constitute substantial
evidence of potential for abuse such as to warrant control or substantial evidence
that the drug or other substance should be removed entirely from the schedules,
he shall initiate proceedings for control or removal, as the case may be, under
subsection (a) of this section.
- (c) Factors determinative of control or removal from schedules
In making any finding under subsection (a) of this section or under subsection
(b) of section 812 of this title, the Attorney General shall consider the following
factors with respect to each drug or other substance proposed to be controlled
or removed from the schedules:
- (1) Its actual or relative potential for abuse.
- (2) Scientific evidence of its pharmacological effect, if known.
- (3) The state of current scientific knowledge regarding the drug or other
substance.
- (4) Its history and current pattern of abuse.
- (5) The scope, duration, and significance of abuse.
- (6) What, if any, risk there is to the public health.
- (7) Its psychic or physiological dependence liability.
- (8) Whether the substance is an immediate precursor of a substance already
controlled under this subchapter.
- (d) International treaties, conventions, and protocols requiring control;
procedures respecting changes in drug schedules of Convention on Psychotropic
Substances
- (1) If control is required by United States obligations under international
treaties, conventions, or protocols in effect on October 27, 1970, the
Attorney General shall issue an order controlling such drug under the
schedule he deems most appropriate to carry out such obligations, without
regard to the findings required by subsection (a) of this section or section
812(b) of this title and without regard to the procedures prescribed by
subsections (a) and (b) of this section.
- (2)
- (A) Whenever the Secretary of State receives notification from the
Secretary-General of the United Nations that information has been
transmitted by or to the World Health Organization, pursuant to article
2 of the Convention on Psychotropic Substances, which may justify
adding a drug or other substance to one of the schedules of the Convention,
transferring a drug or substance from one schedule to another, or
deleting it from the schedules, the Secretary of State shall immediately
transmit the notice to the Secretary of Health and Human Services
who shall publish it in the Federal Register and provide opportunity
to interested persons to submit to him comments respecting the scientific
and medical evaluations which he is to prepare respecting such drug
or substance. The Secretary of Health and Human Services shall prepare
for transmission through the Secretary of State to the World Health
Organization such medical and scientific evaluations as may be appropriate
regarding the possible action that could be proposed by the World
Health Organization respecting the drug or substance with respect
to which a notice was transmitted under this subparagraph.
- (B) Whenever the Secretary of State receives information that the
Commission on Narcotic Drugs of the United Nations proposes to decide
whether to add a drug or other substance to one of the schedules of
the Convention, transfer a drug or substance from one schedule to
another, or delete it from the schedules, the Secretary of State shall
transmit timely notice to the Secretary of Health and Human Services
of such information who shall publish a summary of such information
in the Federal Register and provide opportunity to interested persons
to submit to him comments respecting the recommendation which he is
to furnish, pursuant to this subparagraph, respecting such proposal.
The Secretary of Health and Human Services shall evaluate the proposal
and furnish a recommendation to the Secretary of State which shall
be binding on the representative of the United States in discussions
and negotiations relating to the proposal.
- (3) When the United States receives notification of a scheduling decision
pursuant to article 2 of the Convention on Psychotropic Substances that
a drug or other substance has been added or transferred to a schedule
specified in the notification or receives notification (referred to in
this subsection as a ''schedule notice'') that existing legal controls
applicable under this subchapter to a drug or substance and the controls
required by the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et
seq.) do not meet the requirements of the schedule of the Convention in
which such drug or substance has been placed, the Secretary of Health
and Human Services after consultation with the Attorney General, shall
first determine whether existing legal controls under this subchapter
applicable to the drug or substance and the controls required by the Federal
Food, Drug, and Cosmetic Act, meet the requirements of the schedule specified
in the notification or schedule notice and shall take the following action:
- (A) If such requirements are met by such existing controls but the
Secretary of Health and Human Services nonetheless believes that more
stringent controls should be applied to the drug or substance, the
Secretary shall recommend to the Attorney General that he initiate
proceedings for scheduling the drug or substance, pursuant to subsections
(a) and (b) of this section, to apply to such controls.
- (B) If such requirements are not met by such existing controls and
the Secretary of Health and Human Services concurs in the scheduling
decision or schedule notice transmitted by the notification, the Secretary
shall recommend to the Attorney General that he initiate proceedings
for scheduling the drug or substance under the appropriate schedule
pursuant to subsections (a) and (b) of this section.
- (C) If such requirements are not met by such existing controls and
the Secretary of Health and Human Services does not concur in the
scheduling decision or schedule notice transmitted by the notification,
the Secretary shall -
- (i) if he deems that additional controls are necessary to protect
the public health and safety, recommend to the Attorney General
that he initiate proceedings for scheduling the drug or substance
pursuant to subsections (a) and (b) of this section, to apply
such additional controls;
- (ii) request the Secretary of State to transmit a notice of
qualified acceptance, within the period specified in the Convention,
pursuant to paragraph 7 of article 2 of the Convention, to the
Secretary-General of the United Nations;
- (iii) request the Secretary of State to transmit a notice of
qualified acceptance as prescribed in clause (ii) and request
the Secretary of State to ask for a review by the Economic and
Social Council of the United Nations, in accordance with paragraph
8 of article 2 of the Convention, of the scheduling decision;
or
- (iv) in the case of a schedule notice, request the Secretary
of State to take appropriate action under the Convention to initiate
proceedings to remove the drug or substance from the schedules
under the Convention or to transfer the drug or substance to a
schedule under the Convention different from the one specified
in the schedule notice.
- (4)
- (A) If the Attorney General determines, after consultation with
the Secretary of Health and Human Services, that proceedings initiated
under recommendations made under paragraph (FOOTNOTE 1)
- (B) or (C)(i) of paragraph (3) will not be completed within the
time period required by paragraph 7 of article 2 of the Convention,
the Attorney General, after consultation with the Secretary and after
providing interested persons opportunity to submit comments respecting
the requirements of the temporary order to be issued under this sentence,
shall issue a temporary order controlling the drug or substance under
schedule IV or V, whichever is most appropriate to carry out the minimum
United States obligations under paragraph 7 of article 2 of the Convention.
As a part of such order, the Attorney General shall, after consultation
with the Secretary, except such drug or substance from the application
of any provision of part C of this subchapter which he finds is not
required to carry out the United States obligations under paragraph
7 of article 2 of the Convention. In the case of proceedings initiated
under subparagraph (B) of paragraph (3), the Attorney General, concurrently
with the issuance of such order, shall request the Secretary of State
to transmit a notice of qualified acceptance to the Secretary-General
of the United Nations pursuant to paragraph 7 of article 2 of the
Convention. A temporary order issued under this subparagraph controlling
a drug or other substance subject to proceedings initiated under subsections
(a) and (b) of this section shall expire upon the effective date of
the application to the drug or substance of the controls resulting
from such proceedings. (FOOTNOTE 1) So in original. Probably should
be ''subparagraph''.
- (B) After a notice of qualified acceptance of a scheduling decision
with respect to a drug or other substance is transmitted to the Secretary-General
of the United Nations in accordance with clause (ii) or (iii) of paragraph
(3)(C) or after a request has been made under clause (iv) of such
paragraph with respect to a drug or substance described in a schedule
notice, the Attorney General, after consultation with the Secretary
of Health and Human Services and after providing interested persons
opportunity to submit comments respecting the requirements of the
order to be issued under this sentence, shall issue an order controlling
the drug or substance under schedule IV or V, whichever is most appropriate
to carry out the minimum United States obligations under paragraph
7 of article 2 of the Convention in the case of a drug or substance
for which a notice of qualified acceptance was transmitted or whichever
the Attorney General determines is appropriate in the case of a drug
or substance described in a schedule notice. As a part of such order,
the Attorney General shall, after consultation with the Secretary,
except such drug or substance from the application of any provision
of part C of this subchapter which he finds is not required to carry
out the United States obligations under paragraph 7 of article 2 of
the Convention. If, as a result of a review under paragraph 8 of article
2 of the Convention of the scheduling decision with respect to which
a notice of qualified acceptance was transmitted in accordance with
clause (ii) or (iii) of paragraph (3)(C) -
- (i) the decision is reversed, and
- (ii) the drug or substance subject to such decision is not required
to be controlled under schedule IV or V to carry out the minimum
United States obligations under paragraph 7 of article 2 of the
Convention,
the order issued under this subparagraph with respect to such drug or
substance shall expire upon receipt by the United States of the review
decision. If, as a result of action taken pursuant to action initiated
under a request transmitted under clause (iv) of paragraph (3)(C), the
drug or substance with respect to which such action was taken is not
required to be controlled under schedule IV or V, the order issued under
this paragraph with respect to such drug or substance shall expire upon
receipt by the United States of a notice of the action taken with respect
to such drug or substance under the Convention.
- (C) An order issued under subparagraph (A) or (B) may be issued
without regard to the findings required by subsection (a) of this
section or by section 812(b) of this title and without regard to the
procedures prescribed by subsection (a) or (b) of this section.
(5) Nothing in the amendments made by the Psychotropic Substances Act
of 1978 or the regulations or orders promulgated thereunder shall be
construed to preclude requests by the Secretary of Health and Human
Services or the Attorney General through the Secretary of State, pursuant
to article 2 or other applicable provisions of the Convention, for review
of scheduling decisions under such Convention, based on new or additional
information.
The Attorney General may, without regard to the findings required by subsection
(a) of this section or section 812(b) of this title and without regard to the
procedures prescribed by subsections (a) and (b) of this section, place an immediate
precursor in the same schedule in which the controlled substance of which it
is an immediate precursor is placed or in any other schedule with a higher numerical
designation. If the Attorney General designates a substance as an immediate
precursor and places it in a schedule, other substances shall not be placed
in a schedule solely because they are its precursors.
If, at the time a new-drug application is submitted to the Secretary for any
drug having a stimulant, depressant, or hallucinogenic effect on the central
nervous system, it appears that such drug has an abuse potential, such information
shall be forwarded by the Secretary to the Attorney General.
- (g) Exclusion of non-narcotic substances sold over the counter without
a prescription; dextromethorphan; exemption of substances lacking abuse potential
- (1) The Attorney General shall by regulation exclude any non-narcotic
substance from a schedule if such substance may, under the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), be lawfully sold over
the counter without a prescription.
- (2) Dextromethorphan shall not be deemed to be included in any schedule
by reason of enactment of this subchapter unless controlled after October
27, 1970 pursuant to the foregoing provisions of this section.
- (3) The Attorney General may, by regulation, exempt any compound, mixture,
or preparation containing a controlled substance from the application
of all or any part of this subchapter if he finds such compound, mixture,
or preparation meets the requirements of one of the following categories:
- (A) A mixture, or preparation containing a nonnarcotic controlled
substance, which mixture or preparation is approved for prescription
use, and which contains one or more other active ingredients which
are not listed in any schedule and which are included therein in such
combinations, quantity, proportion, or concentration as to vitiate
the potential for abuse.
- (B) A compound, mixture, or preparation which contains any controlled
substance, which is not for administration to a human being or animal,
and which is packaged in such form or concentration, or with adulterants
or denaturants, so that as packaged it does not present any significant
potential for abuse.
- (h) Temporary scheduling to avoid imminent hazards to public safety
- (1) If the Attorney General finds that the scheduling of a substance
in schedule I on a temporary basis is necessary to avoid an imminent hazard
to the public safety, he may, by order and without regard to the requirements
of subsection (b) of this section relating to the Secretary of Health
and Human Services, schedule such substance in schedule I if the substance
is not listed in any other schedule in section 812 of this title or if
no exemption or approval is in effect for the substance under section
505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355). Such
an order may not be issued before the expiration of thirty days from -
- (A) the date of the publication by the Attorney General of a notice
in the Federal Register of the intention to issue such order and the
grounds upon which such order is to be issued, and
- (B) the date the Attorney General has transmitted the notice required
by paragraph (4).
- (2) The scheduling of a substance under this subsection shall expire at
the end of one year from the date of the issuance of the order scheduling
such substance, except that the Attorney General may, during the pendency
of proceedings under subsection (a)(1) of this section with respect to the
substance, extend the temporary scheduling for up to six months.
- (3) When issuing an order under paragraph (1), the Attorney General shall
be required to consider, with respect to the finding of an imminent hazard
to the public safety, only those factors set forth in paragraphs (4), (5),
and (6) of subsection (c) of this section, including actual abuse, diversion
from legitimate channels, and clandestine importation, manufacture, or distribution.
- (4) The Attorney General shall transmit notice of an order proposed to be
issued under paragraph (1) to the Secretary of Health and Human Services.
In issuing an order under paragraph (1), the Attorney General shall take into
consideration any comments submitted by the Secretary in response to a notice
transmitted pursuant to this paragraph.
- (5) An order issued under paragraph (1) with respect to a substance shall
be vacated upon the conclusion of a subsequent rulemaking proceeding initiated
under subsection (a) of this section with respect to such substance.
- (6) An order issued under paragraph (1) is not subject to judicial review.
§ 812. Schedules of controlled substances.
There are established five schedules of controlled substances, to be known
as schedules I, II, III, IV, and V. Such schedules shall initially consist of
the substances listed in this section. The schedules established by this section
shall be updated and republished on a semiannual basis during the two-year period
beginning one year after October 27, 1970, and shall be updated and republished
on an annual basis thereafter.
- (b) Placement on schedules; findings required
Except where control is required by United States obligations under an international
treaty, convention, or protocol, in effect on October 27, 1970, and except in
the case of an immediate precursor, a drug or other substance may not be placed
in any schedule unless the findings required for such schedule are made with
respect to such drug or other substance. The findings required for each of the
schedules are as follows:
- (1) Schedule I. -
- (A) The drug or other substance has a high potential for abuse.
- (B) The drug or other substance has no currently accepted medical use
in treatment in the United States.
- (C) There is a lack of accepted safety for use of the drug or other
substance under medical supervision.
- (2) Schedule II. -
- (A) The drug or other substance has a high potential for abuse.
- (B) The drug or other substance has a currently accepted medical use
in treatment in the United States or a currently accepted medical use
with severe restrictions.
- (C) Abuse of the drug or other substances may lead to severe psychological
or physical dependence.
- (3) Schedule III. -
- (A) The drug or other substance has a potential for abuse less than
the drugs or other substances in schedules I and II.
- (B) The drug or other substance has a currently accepted medical use
in treatment in the United States.
- (C) Abuse of the drug or other substance may lead to moderate or low
physical dependence or high psychological dependence.
- (4) Schedule IV. -
- (A) The drug or other substance has a low potential for abuse relative
to the drugs or other substances in schedule III.
- (B) The drug or other substance has a currently accepted medical use
in treatment in the United States.
- (C) Abuse of the drug or other substance may lead to limited physical
dependence or psychological dependence relative to the drugs or other
substances in schedule III.
- (5) Schedule V. -
- (A) The drug or other substance has a low potential for abuse relative
to the drugs or other substances in schedule IV.
- (B) The drug or other substance has a currently accepted medical use
in treatment in the United States.
- (C) Abuse of the drug or other substance may lead to limited physical
dependence or psychological dependence relative to the drugs or other
substances in schedule IV.
- (c) Initial schedules of controlled substances
Schedules I, II, III, IV, and V shall, unless and until amended (FOOTNOTE 1)
pursuant to section 811 of this title, consist of the following drugs or other
substances, by whatever official name, common or usual name, chemical name,
or brand name designated: (FOOTNOTE 1) Revised schedules are published in the
Code of Federal Regulations, Part 1308 of Title 21, Food and Drugs.
SCHEDULE I
Unless specifically excepted or unless listed in another schedule, any of the
following opiates, including their isomers, esters, ethers, salts, and salts
of isomers, esters, and ethers, whenever the existence of such isomers, esters,
ethers, and salts is possible within the specific chemical designation:
- (1) Acetylmethadol.
- (2) Allylprodine.
- (3) Alphacetylmathadol. (FOOTNOTE 2) (FOOTNOTE 2) So in original. Probably
should be ''Alphacetylmethadol.''
- (4) Alphameprodine.
- (5) Alphamethadol.
- (6) Benzethidine.
- (7) Betacetylmethadol.
- (8) Betameprodine.
- (9) Betamethadol.
- (10) Betaprodine.
- (11) Clonitazene.
- (12) Dextromoramide.
- (13) Dextrorphan.
- (14) Diampromide.
- (15) Diethylthiambutene.
- (16) Dimenoxadol.
- (17) Dimepheptanol.
- (18) Dimethylthiambutene.
- (19) Dioxaphetyl butyrate.
- (20) Dipipanone.
- (21) Ethylmethylthiambutene.
- (22) Etonitazene.
- (23) Etoxeridine.
- (24) Furethidine.
- (25) Hydroxypethidine.
- (26) Ketobemidone.
- (27) Levomoramide.
- (28) Levophenacylmorphan.
- (29) Morpheridine.
- (30) Noracymethadol.
- (31) Norlevorphanol.
- (32) Normethadone.
- (33) Norpipanone.
- (34) Phenadoxone.
- (35) Phenampromide.
- (36) Phenomorphan.
- (37) Phenoperidine.
- (38) Piritramide.
- (39) Propheptazine.
- (40) Properidine.
- (41) Racemoramide.
- (42) Trimeperidine.
Unless specifically excepted or unless listed in another schedule, any of
the following opium derivatives, their salts, isomers, and salt of isomers whenever
the existence of such salts, isomers, and salts of isomers is possible within
the specific chemical designation:
- (1) Acetorphine.
- (2) Acetyldihydrocodeine.
- (3) Benzylmorphine.
- (4) Codeine methylbromide.
- (5) Codeine-N-Oxide.
- (6) Cyprenorphine.
- (7) Desomorphine.
- (8) Dihydromorphine.
- (9) Etorphine.
- (10) Heroin.
- (11) Hydromorphinol.
- (12) Methyldesorphine.
- (13) Methylhydromorphine.
- (14) Morphine methylbromide.
- (15) Morphine methylsulfonate.
- (16) Morphine-N-Oxide.
- (17) Myrophine.
- (18) Nicocodeine.
- (19) Nicomorphine.
- (20) Normorphine.
- (21) Pholcodine.
- (22) Thebacon.
- (c) Hallucinogenic Substances
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation, which contains any quantity of the following
hallucinogenic substances, or which contains any of their salts, isomers, and
salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
- (1) 3,4-methylenedioxy amphetamine.
- (2) 5-methoxy-3,4-methylenedioxy amphetamine.
- (3) 3,4,5-trimethoxy amphetamine.
- (4) Bufotenine.
- (5) Diethyltryptamine.
- (6) Dimethyltryptamine.
- (7) 4-methyl-2,5-diamethoxyamphetamine.
- (8) Ibogaine.
- (9) Lysergic acid diethylamide.
- (10) Marihuana.
- (11) Mescaline.
- (12) Peyote.
- (13) N-ethyl-3-piperidyl benzilate.
- (14) N-methyl-3-piperidyl benzilate.
- (15) Psilocybin.
- (16) Psilocyn.
- (17) Tetrahydrocannabinols.
SCHEDULE II
Unless specifically excepted or unless listed in another schedule, any of
the following substances whether produced directly or indirectly by extraction
from substances of vegetable origin, or independently by means of chemical synthesis,
or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate, and any salt, compound, derivative, or preparation
of opium or opiate.
- (2) Any salt, compound, derivative, or preparation thereof which is chemically
equivalent or identical with any of the substances referred to in clause (1),
except that these substances shall not include the isoquinoline alkaloids
of opium.
- (3) Opium poppy and poppy straw.
- (4) coca (FOOTNOTE 3) leaves, except coca leaves and extracts of coca leaves
from which cocaine, ecgonine, and derivatives of ecgonine or their salts have
been removed; cocaine, its salts, optical and geometric isomers, and salts
of isomers; ecgonine, its derivatives, their salts, isomers, and salts of
isomers; or any compound, mixture, or preparation which contains any quantity
of any of the substances referred to in this paragraph. (FOOTNOTE 3) So in
original. Probably should be capitalized.
Unless specifically excepted or unless listed in another schedule, any of the
following opiates, including their isomers, esters, ethers, salts, and salts
of isomers, esters and ethers, whenever the existence of such isomers, esters,
ethers, and salts is possible within the specific chemical designation:
- (1) Alphaprodine.
- (2) Anileridine.
- (3) Bezitramide.
- (4) Dihydrocodeine.
- (5) Diphenoxylate.
- (6) Fentanyl.
- (7) Isomethadone.
- (8) Levomethorphan.
- (9) Levorphanol.
- (10) Metazocine.
- (11) Methadone.
- (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane.
- (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
acid.
- (14) Pethidine.
- (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine.
- (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate.
- (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic
acid.
- (18) Phenazocine.
- (19) Piminodine.
- (20) Racemethorphan.
- (21) Racemorphan.
Unless specifically excepted or unless listed in another schedule, any injectable
liquid which contains any quantity of methamphetamine, including its salts,
isomers, and salts of isomers.
SCHEDULE III
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system:
- (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers.
- (2) Phenmetrazine and its salts.
- (3) Any substance (except an injectable liquid) which contains any quantity
of methamphetamine, including its salts, isomers, and salts of isomers.
- (4) Methylphenidate.
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system:
- (1) Any substance which contains any quantity of a derivative of barbituric
acid, or any salt of a derivative of barbituric acid.
- (2) Chorhexadol.
- (3) Glutehimide.
- (4) Lysergic acid.
- (5) Lysergic acid amide.
- (6) Methyprylon.
- (7) Phencyclidine.
- (8) Sulfondiethylmethane.
- (9) Sulfonethylmethane.
- (10) Sulfonmethane.
Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation containing limited quantities of any of the
following narcotic drugs, or any salts thereof:
- (1) Not more than 1.8 grams of codeine per 100 milliliters or not more than
90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
alkaloid of opium.
- (2) Not more than 1.8 grams of codeine per 100 milliliters or not more than
90 milligrams per dosage unit, with one or more active, non-narcotic ingredients
in recognized therapeutic amounts.
- (3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters
or not more than 15 milligrams per dosage unit, with a fourfold or greater
quantity of an isoquinoline alkaloid of opium.
- (4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters
or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts.
- (5) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not
more than 90 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts.
- (6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or
not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts.
- (7) Not more than 500 milligrams of opium per 100 milliliters or per 100
grams, or not more than 25 milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts.
- (8) Not more than 50 milligrams of morphine per 100 milliliters or per 100
grams with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts.
SCHEDULE IV
- (1) Barbital.
- (2) Chloral betaine.
- (3) Chloral hydrate.
- (4) Ethchlorvynol.
- (5) Ethinamate.
- (6) Methohexital.
- (7) Meprobamate.
- (8) Methylphenobarbital.
- (9) Paraldehyde.
- (10) Petrichloral.
- (11) Phenobarbital.
SCHEDULE V
Any compound, mixture, or preparation containing any of the following limited
quantities of narcotic drugs, which shall include one or more nonnarcotic active
medicinal ingredients in sufficient proportion to confer upon the compound,
mixture, or preparation valuable medicinal qualities other than those possessed
by the narcotic drug alone:
- (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100
grams.
- (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or
per 100 grams.
- (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or
per 100 grams.
- (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
of atropine sulfate per dosage unit.
- (5) Not more than 100 milligrams of opium per 100 milliliters or per 100
grams.
§ 813. Treatment of controlled substance analogues.
A controlled substance analogue shall, to the extent intended for human consumption,
be treated, for the purposes of any Federal law as a controlled substance in
schedule I.
§ 814. Removal of exemption of certain drugs.
The Attorney General shall by regulation remove from exemption under section
802(39)(A)(iv) of this title a drug or group of drugs that the Attorney General
finds is being diverted to obtain a listed chemical for use in the illicit production
of a controlled substance.
- (b) Factors to be considered
In removing a drug or group of drugs from exemption under subsection (a) of
this section, the Attorney General shall consider, with respect to a drug or
group of drugs that is proposed to be removed from exemption -
- (1) the scope, duration, and significance of the diversion;
- (2) whether the drug or group of drugs is formulated in such a way that
it cannot be easily used in the illicit production of a controlled substance;
and
- (3) whether the listed chemical can be readily recovered from the drug or
group of drugs.
- (c) Specificity of designation
The Attorney General shall limit the designation of a drug or a group of drugs
removed from exemption under subsection (a) of this section to the most particularly
identifiable type of drug or group of drugs for which evidence of diversion
exists unless there is evidence, based on the pattern of diversion and other
relevant factors, that the diversion will not be limited to that particular
drug or group of drugs.
- (d) Reinstatement of exemption with respect to particular drug products
- (1) Reinstatement On application by a manufacturer of a particular drug
product that has been removed from exemption under subsection (a) of this
section, the Attorney General shall by regulation reinstate the exemption
with respect to that particular drug product if the Attorney General determines
that the particular drug product is manufactured and distributed in a
manner that prevents diversion.
- (2) Factors to be considered In deciding whether to reinstate the exemption
with respect to a particular drug product under paragraph (1), the Attorney
General shall consider -
- (A) the package sizes and manner of packaging of the drug product;
- (B) the manner of distribution and advertising of the drug product;
- (C) evidence of diversion of the drug product;
- (D) any actions taken by the manufacturer to prevent diversion of
the drug product; and
- (E) such other factors as are relevant to and consistent with the
public health and safety, including the factors described in subsection
(b) of this section as applied to the drug product.
- (3) Status pending application for reinstatement A transaction involving
a particular drug product that is the subject of a bona fide pending application
for reinstatement of exemption filed with the Attorney General not later
than 60 days after a regulation removing the exemption is issued pursuant
to subsection (a) of this section shall not be considered to be a regulated
transaction if the transaction occurs during the pendency of the application
and, if the Attorney General denies the application, during the period
of 60 days following the date on which the Attorney General denies the
application, unless -
- (A) the Attorney General has evidence that, applying the factors
described in subsection (b) of this section to the drug product, the
drug product is being diverted; and
- (B) the Attorney General so notifies the applicant.
- (4) Amendment and modification A regulation reinstating an exemption
under paragraph (1) may be modified or revoked with respect to a particular
drug product upon a finding that -
- (A) applying the factors described in subsection (b) of this section
to the drug product, the drug product is being diverted; or
- (B) there is a significant change in the data that led to the issuance
of the regulation.
Return to Controlled Substances Act Table of Contents